BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Orencia abatacept: Phase III data

The double-blind, placebo-controlled, international Phase III ACQUIRE trial in 1,457 patients with moderate to severe RA and an inadequate response to methotrexate showed that weekly subcutaneous injections of Orencia met the primary endpoint of non-inferiority to monthly IV Orencia in the proportion of patients achieving an...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >